Market Research Logo

Hypersensitivity - Pipeline Review, H2 2016

Hypersensitivity - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Hypersensitivity - Pipeline Review, H2 2016’, provides an overview of the Hypersensitivity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Hypersensitivity
    • The report reviews pipeline therapeutics for Hypersensitivity by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Hypersensitivity therapeutics and enlists all their major and minor projects
    • The report assesses Hypersensitivity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Hypersensitivity
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Hypersensitivity
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Hypersensitivity Overview
    Therapeutics Development
    Hypersensitivity - Therapeutics under Development by Companies
    Hypersensitivity - Therapeutics under Investigation by Universities/Institutes
    Hypersensitivity - Pipeline Products Glance
    Hypersensitivity - Products under Development by Companies
    Hypersensitivity - Products under Investigation by Universities/Institutes
    Hypersensitivity - Companies Involved in Therapeutics Development
    Hypersensitivity - Therapeutics Assessment
    Drug Profiles
    Hypersensitivity - Dormant Projects
    Hypersensitivity - Discontinued Products
    Hypersensitivity - Product Development Milestones
    Appendix
    List of Tables
    Number of Products under Development for Hypersensitivity, H2 2016
    Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Development by Companies, H2 2016 (Contd..3)
    Number of Products under Development by Companies, H2 2016 (Contd..4)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Development by Companies, H2 2016 (Contd..4)
    Products under Development by Companies, H2 2016 (Contd..5)
    Products under Development by Companies, H2 2016 (Contd..6)
    Products under Development by Companies, H2 2016 (Contd..7)
    Products under Development by Companies, H2 2016 (Contd..8)
    Products under Investigation by Universities/Institutes, H2 2016
    Hypersensitivity - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016
    Hypersensitivity - Pipeline by Adverum Biotechnologies, Inc., H2 2016
    Hypersensitivity - Pipeline by Aimmune Therapeutics, Inc., H2 2016
    Hypersensitivity - Pipeline by Alfacyte Ltd, H2 2016
    Hypersensitivity - Pipeline by ALK-Abello A/S, H2 2016
    Hypersensitivity - Pipeline by Allakos Inc., H2 2016
    Hypersensitivity - Pipeline by Allergopharma GmbH & Co. KG, H2 2016
    Hypersensitivity - Pipeline by Allergy Therapeutics Plc, H2 2016
    Hypersensitivity - Pipeline by Amgen Inc., H2 2016
    Hypersensitivity - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
    Hypersensitivity - Pipeline by AnaptysBio, Inc., H2 2016
    Hypersensitivity - Pipeline by Anergis SA, H2 2016
    Hypersensitivity - Pipeline by Antigen Express, Inc., H2 2016
    Hypersensitivity - Pipeline by Aravax Pty Ltd, H2 2016
    Hypersensitivity - Pipeline by Array BioPharma Inc., H2 2016
    Hypersensitivity - Pipeline by ASIT biotech s.a., H2 2016
    Hypersensitivity - Pipeline by AskAt Inc., H2 2016
    Hypersensitivity - Pipeline by Astellas Pharma Inc., H2 2016
    Hypersensitivity - Pipeline by BioLingus AG, H2 2016
    Hypersensitivity - Pipeline by Biomay AG, H2 2016
    Hypersensitivity - Pipeline by Biotec Pharmacon ASA, H2 2016
    Hypersensitivity - Pipeline by Boehringer Ingelheim GmbH, H2 2016
    Hypersensitivity - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
    Hypersensitivity - Pipeline by DBV Technologies S.A., H2 2016
    Hypersensitivity - Pipeline by DNJ Pharma, Inc., H2 2016
    Hypersensitivity - Pipeline by EA Pharma Co Ltd, H2 2016
    Hypersensitivity - Pipeline by Enzene Biosciences Ltd., H2 2016
    Hypersensitivity - Pipeline by EpiVax, Inc., H2 2016
    Hypersensitivity - Pipeline by Fountain Biopharma Inc., H2 2016
    Hypersensitivity - Pipeline by HAL Allergy BV, H2 2016
    Hypersensitivity - Pipeline by iCeutica, Inc., H2 2016
    Hypersensitivity - Pipeline by ImmunoFrontier, Inc., H2 2016
    Hypersensitivity - Pipeline by Immunomic Therapeutics, Inc., H2 2016
    Hypersensitivity - Pipeline by Immupharma Plc, H2 2016
    Hypersensitivity - Pipeline by InMed Pharmaceuticals Inc., H2 2016
    Hypersensitivity - Pipeline by Interprotein Corporation, H2 2016
    Hypersensitivity - Pipeline by Japan Tobacco Inc., H2 2016
    Hypersensitivity - Pipeline by JW Pharmaceutical Corporation, H2 2016
    Hypersensitivity - Pipeline by Laboratorios LETI S.L., H2 2016
    Hypersensitivity - Pipeline by Monosol Rx, LLC, H2 2016
    Hypersensitivity - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
    Hypersensitivity - Pipeline by Neovacs SA, H2 2016
    Hypersensitivity - Pipeline by Novartis AG, H2 2016
    Hypersensitivity - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
    Hypersensitivity - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
    Hypersensitivity - Pipeline by REGiMMUNE Corporation, H2 2016
    Hypersensitivity - Pipeline by Roxall Medizin GmbH, H2 2016
    Hypersensitivity - Pipeline by Sanofi, H2 2016
    Hypersensitivity - Pipeline by Sealife PHARMA GMBH, H2 2016
    Hypersensitivity - Pipeline by Stallergenes Greer plc, H2 2016
    Hypersensitivity - Pipeline by Stallergenes SAS, H2 2016
    Hypersensitivity - Pipeline by Swecure AB, H2 2016
    Hypersensitivity - Pipeline by Therabron Therapeutics, Inc., H2 2016
    Hypersensitivity - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016
    Hypersensitivity - Pipeline by Toleranzia AB, H2 2016
    Hypersensitivity - Pipeline by United Biomedical, Inc., H2 2016
    Hypersensitivity - Pipeline by United BioPharma, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Hypersensitivity - Dormant Projects, H2 2016
    Hypersensitivity - Dormant Projects (Contd..1), H2 2016
    Hypersensitivity - Dormant Projects (Contd..2), H2 2016
    Hypersensitivity - Dormant Projects (Contd..3), H2 2016
    Hypersensitivity - Dormant Projects (Contd..4), H2 2016
    Hypersensitivity - Dormant Projects (Contd..5), H2 2016
    Hypersensitivity - Dormant Projects (Contd..6), H2 2016
    Hypersensitivity - Dormant Projects (Contd..7), H2 2016
    Hypersensitivity - Dormant Projects (Contd..8), H2 2016
    Hypersensitivity - Dormant Projects (Contd..9), H2 2016
    Hypersensitivity - Dormant Projects (Contd..10), H2 2016
    Hypersensitivity - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Hypersensitivity, H2 2016
    Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Top 10 Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report